Dennis TL Ku

Dr. Dennis TL Ku

Department of Paediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, China
orcid
Paediatric Haematology & Oncology

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
ALAnna Lin
Anna Lin
FCFrankie W.T. Cheng
Frankie W.T. Cheng
ACAlan K.S. Chiang
Alan K.S. Chiang
CLChung‐Wing Luk
Chung‐Wing Luk
RLRever C.H. Li
Rever C.H. Li
Chi Kong LiChi Kong Li
Chi Kong Li

4 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YWYuliang Wang Wang
Yuliang Wang Wang
ALAnthony Pak Yin Liu
Anthony Pak Yin Liu
TLTatia M.c. Lee
Tatia M.c. Lee
WWWilfred Hing Sang Wong
Wilfred Hing Sang Wong
Daniel FongDaniel Fong
Daniel Fong
WTWinnie Wan-Yee Tso
Winnie Wan-Yee Tso
Purpose: The neurocognitive outcomes of pediatric brain tumor survivors have been extensively studied but the risk and predictors for neurobehavioral impairment are less clearly defined. We systematically analyzed the rates of emotional, psychosocial, and attention problems in pediatric brain tumor survivors. Methods: PubMed, Web of Science, Embase, Scopus, and Cochrane were searched for articles published between January 2012 to April 2022. Eligible studies reported neurobehavioral outcomes for PBTS aged 2 to <23 years with a brain tumor diagnosis before 18 years of age. A random-effect meta-analysis was performed in R. Results: The search yielded 1187 unique publications, of which 50 were included in the quantitative analysis. The estimated risk of having emotional, psychosocial, and attention problems were 15% (95%CI 10–20%), 12% (95%CI 9–16%), and 12% (95%CI 9–16%), respectively. PBTS were more likely to have emotional difficulties (Hedge’s g = 0.43 [95%CI 0.34–0.52]), psychosocial problems (Hedge’s g = 0.46 [95%CI 0.33–0.58]), and attention problems (Hedge’s g = 0.48 [95%CI 0.34–0.63]) compared to normal/healthy control subjects. There was no significant difference in the rates of neurobehavioral impairment between children with and without history of cranial radiotherapy. Conclusions: PBTS are at elevated risk of neurobehavioral impairment. Neurobehavioral monitoring should be considered as the standard of care for PBTS.

28 April 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
WCWilson Y. K. Chan
Wilson Y. K. Chan
NFNg Wai Fu
Ng Wai Fu
EFEric C. H. Fu
Eric C. H. Fu
ALAnthony Pak Yin Liu
Anthony Pak Yin Liu
CYCarol L. S. Yan
Carol L. S. Yan
WLWing Leung
Wing Leung

7 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OTOtto Chun Ho Tam
Otto Chun Ho Tam
RHRonnie S. L. Ho
Ronnie S. L. Ho
SCShing Chan
Shing Chan
KLKay Ka-Wai Li
Kay Ka-Wai Li
TLTit-Leung Lam
Tit-Leung Lam
ALAnthony Pak Yin Liu
Anthony Pak Yin Liu
This paper examines the link between CNS tumor biology and heterogeneity and the use of genome-wide DNA methylation profiling as a clinical diagnostic platform. CNS tumors are the most common solid tumors in children, and their prognosis remains poor. This study retrospectively analyzed pediatric patients with CNS embryonal tumors in Hong Kong between 1999 and 2017, using data from the territory-wide registry and available formalin-fixed paraffin-embedded tumor tissue. After processing archival tumor tissue via DNA extraction, quantification, and methylation profiling, the data were analyzed by using the web-based DKFZ classifier (Molecular Neuropathology (MNP) 2.0 v11b4) and t-SNE analysis. Methylation profiles were deemed informative in 85 samples. Epigenetic data allowed molecular subgrouping and confirmed diagnosis in 65 samples, verified histologic diagnosis in 8, and suggested an alternative diagnosis in 12. This study demonstrates the potential of DNA methylation profiling in characterizing pediatric CNS embryonal tumors in a large cohort from Hong Kong, which should enable regional and international collaboration in future pediatric neuro-oncology research.

7 February 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
TWTania Wan
Tania Wan
JTJoanna Yuet‐Ling Tung
Joanna Yuet‐Ling Tung
AMAlison Ma
Alison Ma
SLSamantha Lai‐Ka Lee
Samantha Lai‐Ka Lee
ALAnthony Pak Yin Liu
Anthony Pak Yin Liu
MSMatthew Ming‐Kong Shing
Matthew Ming‐Kong Shing

4 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ELEvelyn Lu
Evelyn Lu
PCPui Wai Cheng
Pui Wai Cheng
SLSherman S. M. Lo
Sherman S. M. Lo
CSChloe W. Y. Siu
Chloe W. Y. Siu
CFChun ho Eric Fu
Chun ho Eric Fu
DSDeyond Y.W. Siu
Deyond Y.W. Siu
Background: Amino acid tracer positron emission tomography–magnetic resonance imaging (PET-MRI) was shown to be superior to MRI alone for evaluating central nervous system (CNS) tumours in adults. This study aimed to investigate the utility of amino acid PET-MRI in children with CNS tumours. Methods: We reviewed the amino acid PET-MRI findings of children with suspected or confirmed CNS neoplasms managed in a territory-wide referral centre in Hong Kong from 2022 to 2025. Maximal standardized uptake values (SUVmax) were captured, and tumour-to-background SUVmax ratios (TBRmax) were measured with reference to adjacent or contralateral normal brain structures. Comparisons were made among patients with clinical high-grade and low-grade/non-neoplastic lesions. Results: Thirty-seven patients were included, with 63 PET-MRIs performed. PET-MRI was performed as part of initial diagnostics in 41% of the cases, for response assessment in 48%, and evaluation of residual/relapsed disease in 11%. High-grade lesions had a significantly higher SUVmax and TBRmax compared to low-grade/non-malignant lesions (median SUVmax 3.7 vs. 1.6, p = 0.00006; median TBRmax 2.06 vs. 0.91, p = 0.00002). Optimal SUVmax and TBRmax cut-offs by ROC analysis were 2.38 and 1.62, respectively. Similar performance was reproduced by focusing on the subset of patients with suspected CNS germ cell tumours (CNS-GCT). The impact of amino acid PET availability is considerable, as clinical management was modified in 65% of patients. Conclusions: Our study demonstrates the performance and clinical utility of amino acid PET-MRI in the management of children with CNS pathologies. Amino acid PET-MRI contributes to the diagnosis, monitoring, and treatment guidance of these patients, providing crucial information for decision-making.